Lataa...

The RAS-effector interaction as a drug target

About a third of all human cancers harbor mutations in one of the K-, N-, or HRAS genes that encode an abnormal RAS protein locked in a constitutively activated state to drive malignant transformation and tumor growth. Despite more than three decades of intensive research aimed at the discovery of R...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Keeton, Adam B., Salter, E. Alan, Piazza, Gary A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5243175/
https://ncbi.nlm.nih.gov/pubmed/28062402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-0938
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!